Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 893 (final count)
- Started
- May 10, 2021
- Main results expected
- Nov 1, 2027
- Fully finished
- Aug 14, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.
Measured over: Within the first 28 day cycle.
Phase Ib: 2. The number of participants with treatment-related adverse events.
Measured over: From baseline up to approximately 36 months.
Phase Ib: 3. The number of participants with treatment-related serious adverse events.
Measured over: From baseline up to approximately 36 months.
Phase III: 1. Progression Free Survival (PFS).
Measured over: Up to approximately 47 months.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04862663 · record last updated 2026-08-17 · checked 2026-11-09 15:47 UTC